|
1
|
Packer RJ, Zhou T, Holmes E, Vezina G and
Gajjar A: Survival and secondary tumors in children with
medulloblastoma receiving radiotherapy and adjuvant chemotherapy:
Results of children's oncology group trial A9961. Neuro Oncol.
15:97–103. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jakacki RI, Burger PC, Zhou T, Holmes EJ,
Kocak M, Onar A, Goldwein J, Mehta M, Packer RJ, Tarbell N, et al:
Outcome of children with metastatic medulloblastoma treated with
carboplatin during craniospinal radiotherapy: A children's oncology
group phase I/II study. J Clin Oncol. 30:2648–2653. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gajjar A, Chintagumpala M, Ashley D,
Kellie S, Kun LE, Merchant TE, Woo S, Wheeler G, Ahern V, Krasin
MJ, et al: Risk-adapted craniospinal radiotherapy followed by
high-dose chemotherapy and stem-cell rescue in children with newly
diagnosed medulloblastoma (St Jude Medulloblastoma-96): Long-term
results from a prospective, multicentre trial. Lancet Oncol.
7:813–820. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gerson SL: MGMT: Its role in cancer
aetiology and cancer therapeutics. Nat Rev Cancer. 4:296–307. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Faoro D, von Bueren AO, Shalaby T,
Sciuscio D, Hürlimann ML, Arnold L, Gerber NU, Haybaeck J,
Mittelbronn M, Rutkowski S, et al: Expression of
O6-methylguanine-DNA methyltransferase in childhood
medulloblastoma. J Neurooncol. 103:59–69. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Malley DS, Hamoudi RA, Kocialkowski S,
Pearson DM, Collins VP and Ichimura K: A distinct region of the
MGMT CpG island critical for transcriptional regulation is
preferentially methylated in glioblastoma cells and xenografts.
Acta Neuropathol. 121:651–661. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hegi ME, Diserens AC, Gorlia T, Hamou MF,
de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani
L, et al: MGMT gene silencing and benefit from temozolomide in
glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Donson AM, Addo-Yobo SO, Handler MH, Gore
L and Foreman NK: MGMT promoter methylation correlates with
survival benefit and sensitivity to temozolomide in pediatric
glioblastoma. Pediatr Blood Cancer. 48:403–407. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rood BR, Zhang H and Cogen PH:
Intercellular heterogeneity of expression of the MGMT DNA repair
gene in pediatric medulloblastoma. Neuro Oncol. 6:200–207. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Neben K, Korshunov A, Benner A, Wrobel G,
Hahn M, Kokocinski F, Golanov A, Joos S and Lichter P:
Microarray-based screening for molecular markers in medulloblastoma
revealed STK15 as independent predictor for survival. Cancer Res.
64:3103–3111. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
von Bueren AO, Bacolod MD, Hagel C,
Heinimann K, Fedier A, Kordes U, Pietsch T, Koster J, Grotzer MA,
Friedman HS, et al: Mismatch repair deficiency: A temozolomide
resistance factor in medulloblastoma cell lines that is uncommon in
primary medulloblastoma tumours. Br J Cancer. 107:1399–1408. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bobola MS, Silber JR, Ellenbogen RG, Geyer
JR, Blank A and Goff RD: O6-methylguanine-DNA methyltransferase,
O6-benzylguanine, and resistance to clinical alkylators in
pediatric primary brain tumor cell lines. Clin Cancer Res.
11:2747–2755. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jabeen S, Holmboe L, Alnaes GI, Andersen
AM, Hall KS and Kristensen VN: Impact of genetic variants of RFC1,
DHFR and MTHFR in osteosarcoma patients treated with high-dose
methotrexate. Pharmacogenomics J. 15:385–390. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Preusser M, Charles Janzer R, Felsberg J,
Reifenberger G, Hamou MF, Diserens AC, Stupp R, Gorlia T, Marosi C,
Heinzl H, et al: Anti-O6-methylguanine-methyltransferase (MGMT)
immunohistochemistry in glioblastoma multiforme: Observer
variability and lack of association with patient survival impede
its use as clinical biomarker. Brain Pathol. 18:520–532.
2008.PubMed/NCBI
|
|
15
|
Everhard S, Tost J, El Abdalaoui H,
Crinière E, Busato F, Marie Y, Gut IG, Sanson M, Mokhtari K,
Laigle-Donadey F, et al: Identification of regions correlating MGMT
promoter methylation and gene expression in glioblastomas. Neuro
Oncol. 11:348–356. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kanemoto M, Shirahata M, Nakauma A,
Nakanishi K, Taniguchi K, Kukita Y, Arakawa Y, Miyamoto S and Kato
K: Prognostic prediction of glioblastoma by quantitative assessment
of the methylation status of the entire MGMT promoter region. BMC
Cancer. 14:6412014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Northcott PA, Korshunov A, Witt H,
Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, Hawkins
CE, French P, et al: Medulloblastoma comprises four distinct
molecular variants. J Clin Oncol. 29:1408–1414. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Taylor MD, Northcott PA, Korshunov A,
Remke M, Cho YJ, Clifford SC, Eberhart CG, Parsons DW, Rutkowski S,
Gajjar A, et al: Molecular subgroups of medulloblastoma: The
current consensus. Acta Neuropathol. 123:465–472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Grombacher T, Mitra S and Kaina B:
Induction of the alkyltransferase (MGMT) gene by DNA damaging
agents and the glucocorticoid dexamethasone and comparison with the
response of base excision repair genes. Carcinogenesis.
17:2329–2336. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cefalo G, Massimino M, Ruggiero A, Barone
G, Ridola V, Spreafico F, Potepan P, Abate ME, Mascarin M, Garrè
ML, et al: Temozolomide is an active agent in children with
recurrent medulloblastoma/primitive neuroectodermal tumor: An
Italian multi-institutional phase II trial. Neuro Oncol.
16:748–753. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nicholson HS, Kretschmar CS, Krailo M,
Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok
N, Mazewski C, et al: Phase 2 study of temozolomide in children and
adolescents with recurrent central nervous system tumors: A report
from the Children's Oncology Group. Cancer. 110:1542–1550. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Grill J, Geoerger B, Gesner L, Perek D,
Leblond P, Cañete A, Aerts I, Madero L, de Toledo Codina JS,
Verlooy J, et al: Phase II study of irinotecan in combination with
temozolomide (TEMIRI) in children with recurrent or refractory
medulloblastoma: A joint ITCC and SIOPE brain tumor study. Neuro
Oncol. 15:1236–1243. 2013. View Article : Google Scholar : PubMed/NCBI
|
